2013

  • Quinn KM, Da Costa A, Yamamoto A, Berry D, Lindsay RW, Darrah PA, Wang L, Cheng C, Kong WP, Gall JG, Nicosia A, Folgori A, Colloca S, Cortese R, Gostick E, Price DA, Gomez CE, Esteban M, Wyatt LS, Moss B, Morgan C, Roederer M, Bailer RT, Nabel GJ, Koup RA, Seder RA. 2013. Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization.J Immunol. Feb 6. [Epub ahead of print].
  • Sánchez-Sampedro L, Gómez CE, Mejías-Pérez E, Pérez-Jiménez E, Oliveros JC, Esteban M. Attenuated and replication competent Vaccinia Virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens. J Virol. 2013 Apr 17. [Epub ahead of print].
  • Gómez CE, Perdiguero B, Cepeda MV, Mingorance L, García-Arriaza J, Vandermeeren A, Sorzano CO, Esteban M. High, broad, polyfunctional and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate based on MVA expressing the near full-length HCV genome (MVA-HCV). J Virol. 2013 Apr 17. [Epub ahead of print].
  • Garcia-Arriaza, J.F., Arnaez P., Gomez C.E., Sorzano C.O and Esteban M. 2013. Improving adaptive and memory immune responses of an HIV/AIDS vaccine candidate MVA-B by deletion of vaccinia virus genes (C6L and K7R) blocking interferon signaling pathways. PloS ONE (in press).
  • Caceres A., Perdiguero B., Gomez C.E., Cepeda M., Caelles, C., Sorzano CO, and Esteban M 2013. Involvement of the cellular phosphatase DUSP1 in vaccinia virus infection. PloS Pathogens (under revision).
  • Emilio Yángüez, Alicia García-Culebras, Aldo Frau, Catalina Llompart, Klaus-Peter Knobeloch, Sylvia Gutierrez-Erlandsson, Adolfo García-Sastre, Mariano Esteban, Amelia Nieto and Susana Guerra 2013. ISG15 regulates peritoneal macrophages functionality against viral infection (PLoS Pathogens, under revision).
  • Mauro Di Pilato , Ernesto Mejías-Pérez , Carmen Elena Gómez , Beatriz Perdiguero, Carlos Oscar S. Sorzano and Mariano Esteban 2013. New vaccinia virus promoter as candidate for future vaccines (J. Virol, under revision).
  • Beatriz Perdiguero, Carmen Elena Gómez, Carlos Oscar S. Sorzano, Julie Delaloye, Thierry Roger, Thierry Calandra, Giuseppe Pantaleo, and Mariano Esteban 2013. Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR4 signaling, is an effective approach to enhance the immunogenicity of the HIV/AIDS vaccine candidate NYVAC-C (PloS ONE, submitted)

2012

  • Chichon J.F., Rodriguez M.J., Pereiro E., Chiapi M., Perdiguero B., Guttman S., Rehbein S., Scheneider G., Esteban M, and Carrascosa J.L. 2012. Cryo X-ray nano-tomography of vaccinia virus infected cells. J Struct Biol 177, 202-211.
  • Falivene J, Del Médico Zajac MP, Pascutti MF, Rodríguez AM, Maeto C, Perdiguero B, Gómez CE, Esteban M, Calamante G, Gherardi MM 2012. Improving the MVA Vaccine Potential by Deleting the Viral Gene Coding for the IL-18 Binding Protein. PLoS ONE. 2012;7(2):e32220.
  • Gómez CE, Perdiguero B, Jiménez V, Filali-Mouhim A, Ghneim K, Haddad EK, Quakkelaar ED, Delaloye J, Harari A, Roger T, Duhen T, Sékaly RP, Melief CJ, Calandra T, Sallusto F, Lanzavecchia A, Wagner R, Pantaleo G, Esteban M. 2012. Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C. PLoS ONE 7(4): e35485.
  • Rodríguez D, González-Aseguinolaza G, Rodríguez JR, Vijayan A, Gherardi M, Rueda P, Casal JI, Esteban M. 2012. Vaccine Efficacy against Malaria by the Combination of Porcine Parvovirus-Like Particles and Vaccinia Virus Vectors Expressing CS of Plasmodium. PLoS ONE 7(4): e34445
  • Gómez CE, Perdiguero B, Nájera JL, Sorzano CO, Jiménez V, González-Sanz R, Esteban M. 2012. Removal of Vaccinia Virus Genes That Block Interferon Type I and II Pathways Improves Adaptive and Memory Responses of the HIV/AIDS Vaccine Candidate NYVAC-C in Mice. J. Virol 86, 5026-5038.
  • Vijayan A, Gómez CE, Espinosa DA, Goodman AG, Sanchez-Sampedro L, Sorzano CO, Zavala F, Esteban M. 2012. Adjuvant-like Effect of Vaccinia Virus 14K Protein: A Case Study with Malaria Vaccine Based on the Circumsporozoite Protein. J Immunol. 15;188(12):6407-17.
  • Elena Gómez C, Perdiguero B, Garcia-Arriaza J, Esteban M. Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother. 2012 Sep 1;8(9).
  • Sánchez-Sampedro L, Gómez CE, Mejías-Pérez E, Sorzano CO, Esteban M. 2012. High Quality Long-Term CD4(+) and CD8(+) Effector Memory Populations Stimulated by DNA-LACK/MVA-LACK Regimen in Leishmania major BALB/c Model of Infection.PLoS ONE;7(6):e3885.
  • Lucero, M.C., Diaz-Brito, V., Murillo, B. YT., Carretero S. C., Sala M., Casadesús, C., Conde M. S., Jimenez J. L., Pich J., Arnaiz J. A., Leon A., Perez I., Muñoz-Fernandez M. A., Gatell J. M., Plana M., Esteban M., Bernaldo de Quiros J. C and Garcia F. 2012. Reasons for Not Participating in a Phase 1 Preventive HIV Vaccine Study in a Resource-Rich Country. AIDS Patient Care STDS (7):379-382.
  • García-Arriaza J, Arnáez P, Jiménez JL, Gómez CE, Muñoz-Fernández MÁ, Esteban M. 2012. Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors. Virus Res. 167(2):391-6.
  • Pattacini L, Mize GJ, Graham JB, Fluharty TR, Graham TM, Lingnau K, Wizel B, Perdiguero B, Esteban M, Pantaleo G, Shen M, Spies GA, McElrath MJ, Lund JM 2012. A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity. PLoS One ;7(7):e42163.
  • González-Santamaría J, Campagna M, Ortega-Molina A, Marcos-Villar L, de la Cruz-Herrera CF, González D, Gallego P, Lopitz-Otsoa F, Esteban M, Rodríguez MS, Serrano M, Rivas C. 2012. Regulation of the tumor suppressor PTEN by SUMO. Cell Death Dis. 27;3:e393.
  • Perdiguero B, Gómez CE, Nájera JL, Sorzano CO, Delaloye J, González-Sanz R, Jiménez V, Roger T, Calandra T, Pantaleo G, Esteban M. 2012. Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens. PLoS One ;7(10):e48524.

2011

  • Krupa, M., Canamero, M., Gomez, C.E., Najera, J.L and Esteban, M . 2011. Immunization with DNA and vaccinia virus MVA vectors expressing PSCA and STEAP antigens reduces prostate cancer development. Vaccine 29, 1504-1513
  • Flynn B.J., Kastenmueller K., Willie-Reece U., Tamara, G.D., Munir Alam S., Lindsay R.W.B., Salazar, A., Perdiguero B., Gomez C.E., Esteban M., Park C.G., Trumpfheller C., Keler T., Pantaleo G., Steinman R.M, and Seder R.A 2011. Prime-boost immunization with protein targeted to the dendrtici cell receptor DEC205 followed by recombinant NYVAC induces robust Gag CD4 and CD8+ T cell responses in non human primates . PNAS ( submitted)
  • Domingo-Gil, E. Toribio, R., Najera, JL, Esteban, M, and Ventoso, I 2011. Diversity in viral anti-PKR mechanisms: a remarkable case of evolutionary convergence.. PloS ONE 6, e16711
  • Quakkelaar, E.D., Redeker, A., Haddad, E. K., Harari, A., McCaughey, S. M., Duhen, T., Filali-Mouhim, A., Goulet, J-P., Loof, N. M., Ossendorp, F., Perdiguero, B., Heinen, P., Gomez, C.E., Kibler, K. V., Koelle, D. M., SŽkaly, R. P., Sallusto, F., Lanzavecchia, A., Pantaleo, G., Esteban, M., Tartaglia, J., Jacobs, B. L, and Melief, C. J. M 2011. Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PloS ONE 6, e16819.
  • Daniela C. Monaco, Ana M. Rodriguez, Maria F. Pascutti, Mauricio Carobene, Juliana Falivene, Alejandro Gomez, Cynthia Maeto, Gabriela Turk, Jose L. Najera, Mariano Esteban, M. Magdalena Gherardi 2011. T-Cell Immune Responses Against Env from CRF12_BF and Subtype B HIV-1 Show High Clade-Specificity that Can Be Overridden by Multiclade Immunizations.. PloS ONE 66 (2): e17185.
  • Climent, N., Guerra, S., García, F., Rovira, C., Miralles, L., Gómez, C.E., Piqué, N., Gil, C., Gatell, J.M., Esteban, M, and Gallart, T. 2011. Dendritic cells exposed with MVA-based HIV-1 vaccine induce highly polyfunctional HIV-1-specific CD8+ T cell response in HIV-1-infected individuals. PLoS ONE 6 (5): e19644
  • García F, Bernaldo de Quirós JC, Gómez CE, Perdiguero B, Nájera JL, Jiménez V, García-Arriaza J, Guardo AC, Pérez I, Díaz-Brito V, Conde MS, González N, Alvarez A, Alcamí J, Jiménez JL, Pich J, Arnaiz JA, Maleno MJ, León A, Muñoz-Fernández MA, Liljeström P, Weber J, Pantaleo G, Gatell JM, Plana M, Esteban M. 2011. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing env, gag, pol, nef proteins of HIV-1 subtype B (MVA-B) in HIV-1-uninfected volunteers. Vaccine 29, 8309-8316
  • Gómez CE, Nájera JL, Perdiguero B, García-Arriaza J, Sorzano CO, Jiménez V, González-Sanz R, Jiménez JL, Muñoz-Fernández MA, López Bernaldo de Quirós JC, Guardo AC, García F, Gatell JM, Plana M, Esteban M. 2011. The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional and selective effector memory T cell responses to HIV-1 antigens. Journal Virology 85, 11468-11478.
  • Juan García-Arriaza, José Luis Nájera, Carmen E. Gómez, Nolawit Tewabe, Carlos Oscar S. Sorzano, Thierry Calandra, Thierry Roger, Mariano Esteban 2011. A candidate HIV/AIDS vaccine MVA-B with a deletion in the vaccinia virus gene C6L induces IFN-B and enhances the magnitude and polyfunctionality of memory HIV-1 specific T-cell responses. PLoS ONE. 2011;6(8):e24244
  • Perreau M., Welles H.C., Harari A., Hall O., Martin R., Maillard M., Dorta G., Bart P-A., Kremer E-J., Tartaglia J., Wagner R., Esteban M., Levy I, and Pantaleo G. 2011. DNA-C/NYVAC-C vaccine regimen induces HIV-specific CD4 and CD8 T cell-responses in intestinal mucosa. J. Virol 85, 9854-9862
  • Alan G. Goodman., Bertrand C Tanner., Stewart T Chang., Mariano Esteban and Michael G Katze 2011. Virus infection rapidly activates the p58IPK pathway, delaying peak kinase activation to enhance viral replication. Virology 417, 27-36
  • González-Santamaría J, Campagna M, García MA, Marcos-Villar L, González D, Gallego P, Lopitz-Otsoa F, Guerra S, Rodríguez M, Esteban M, Rivas C. 2011. Regulation of vaccinia virus E3 protein by SUMO. J Virol. 85:12890-900.
  • Goodman A. G., Heinen P.P., Guerra S., Vijayan A., Sorzano CO., Gomez C.E and Esteban M. 2011. A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virus. PLoS ONE 6, 10. e25938
  • Kibler KV, Gomez CE, Perdiguero B, Wong S, Huynh T, Holechek S, Arndt W, Jimenez V, Gonzalez-Sanz R, Denzler K, Haddad EK, Wagner R, Sékaly RP, Tartaglia J, Pantaleo G, Jacobs BL, Esteban M. 2011. Improved NYVAC-Based Vaccine Vectors. PLoS ONE. 2011;6(11):e25674.
  • Gómez CE, Nájera JL, Krupa M, Perdiguero B, Esteban M. 2011. MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther. 11(3):189-217. Review.
  • Guerra S, Abaitua F, Martínez-Sobrido L, Esteban M, García-Sastre A, Rodríguez D 2011. Host-Range Restriction of Vaccinia Virus E3L Deletion Mutant Can Be Overcome In Vitro, but Not In Vivo, by Expression of the Influenza Virus NS1 Protein. PLoS ONE. 2011;6(12):e28677.

2010

  • Domingo-Gil,., Gonzalez, J.M, and Esteban, M. 2010. Identification of cellular genes induced in human cells after activation of the OAS/RNaseL pathway by vaccinia virus recombinants expressing these antiviral enzymes. J. Interferon Cytokine Res 30, 171-188 30, 171-188
  • Gonzalez, J.M, and Esteban, M 2010. A poxvirus Bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history Virology Journal 7: 59
  • Guerra, S., Gonzalez, J.M., Climent, N., Reyburn, H., Lopez-Fernandez, L.A., Najera, J.L., Gomez, C.E., Garcia, F., Gatell, J.M., Gallart, T, and Esteban, M . 2010. Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS. J. Virol 84. Guerra_JVI_2010.pdf
  • Najera, J.L., Gomez, C.E., Garcia-Arriaza, J, and Esteban, M 2010. Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens.PloS ONE. (in press).
  • Campagna, M., Herranz, D., Garcia, M.A., Marcos-Villar, L., Gonzalez-Santamaria, J., Gallego, P., Gutierrez, S., Collado, M., Serrano, M., Esteban, M, and Rivas, C. 2010. SIRT1 stablizes PML promoting its sumoylation. Cell Death and Differentiation.
  • Perdiguero, B and Esteban, M . 2010. Poxviruses and interferon Chapter book by Horizon Press entitled "Viruses and Interferon: Current Research" (in press)
  • Garcia, MA., Krupa, M and Esteban, M 2010. Antitumoral activity of oncolytic vaccinia virus expressing the interferon-induced ds-RNA dependent protein kinase PKR.Anal. Real Acad. Nac. Farm. (in press)
  • Pantaleo, G., Esteban, M., Jacobs, B and Tartaglia, J 2010. Poxvirus vector-based vaccines.In Curr. Opin. HIV AIDS. (in press)
  • Garcia-Arriaza, J., Najera, J.L., Gomez, C.E, and Esteban, M Immunogenic profiling in mice of an candidate HIV/AIDS vaccine candidate (MVA-B) expressing four HIV antigens and potentiation by specific gene deletions.PLoS ONE 5 (8): e12395.
  • Wilks AB, Christian EC, Seaman MS, Sircar P, Carville A, Gomez CE, Esteban M, Pantaleo G, Barouch DH, Letvin NL, Permar SR 2010. Robust Vaccine-Elicited Cellular Immune Responses in Breast Milk following Systemic Simian Immunodeficiency Virus DNA Prime and Live Virus Vector Boost Vaccination of Lactating Rhesus MonkeysJ. Immunol 185, 7097-7106.
  • Wilks AB, Christian EC, Seaman MS, Sircar P, Carville A, Gomez CE, Esteban M, Pantaleo G, Barouch DH, Letvin NL, Permar SR 2010. Robust Vaccine-Elicited Cellular Immune Responses in Breast Milk following Systemic Simian Immunodeficiency Virus DNA Prime and Live Virus Vector Boost Vaccination of Lactating Rhesus MonkeysJ. Immunol 185, 7097-7106.

2009

  • M. Esteban. 2009. Un Nobel esperado: descubrimiento de los agentes causales del SIDA y cáncer cervical An. R. Acad. Nac. Farm. 75, 77-98
  • J. V. Cordeiro, S. Guerra, Y. Arakawa, M. P. Dodding, M. Esteban and M. Way. 2009. F11-mediated inhibition of RhoA signalling enhances the spread of vaccinia virus in vitro and in vivo in an intranasal mouse model of infection. PLoS One 4, e8506
  • E. Domingo-Gil, J. M. Gonzalez and M. Esteban. 2009. Identification of Cellular Genes Induced in Human Cells After Activation of the OAS/RNaseL Pathway by Vaccinia Virus Recombinants Expressing These Antiviral Enzymes. J Interferon Cytokine Res
  • M. Esteban. 2009. Hepatitis C and evasion of the interferon system: a PKR paradigm. Cell Host Microbe 6, 495-7
  • V. Cepeda, M. Esteban and A. Fraile-Ramos. 2009. Human cytomegalovirus final envelopment on membranes containing both trans-Golgi network and endosomal markers. Cell Microbiol
  • M. Esteban. 2009. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Hum Vaccin 5, 87-92
  • J. Wild, K. Bieler, J. Kostler, M. J. Frachette, S. Jeffs, S. Vieira, M. Esteban, P. Liljestrom, G. Pantaleo, H. Wolf and R. Wagner. 2009. Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model. Viral Immunol 22, 309-19
  • B. Perdiguero and M. Esteban. 2009. The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res 29, 581-98
  • A. M. Rodriguez, G. Turk, M. F. Pascutti, F. Ferrer, J. L. Najera, D. Monaco, M. Esteban, H. Salomon, G. Calamante and M. M. Gherardi. 2009. Characterization of DNA and MVA vectors expressing Nef from HIV-1 CRF12_BF revealed high immune specificity with low cross-reactivity against subtype B. Virus Res 146, 1-12
  • M. A. Garcia, P. Gallego, M. Campagna, J. Gonzalez-Santamaria, G. Martinez, L. Marcos-Villar, A. Vidal, M. Esteban and C. Rivas. 2009. Activation of NF-kB pathway by virus infection requires Rb expression. PLoS One 4, e6422
  • J. L. Carrascosa, F. J. Chichon, E. Pereiro, M. J. Rodriguez, J. J. Fernandez, M. Esteban, S. Heim, P. Guttmann and G. Schneider. 2009. Cryo-X-ray tomography of vaccinia virus membranes and inner compartments. J Struct Biol 168, 234-9
  • J. Delaloye, T. Roger, Q. G. Steiner-Tardivel, D. Le Roy, M. Knaup Reymond, S. Akira, V. Petrilli, C. E. Gomez, B. Perdiguero, J. Tschopp, G. Pantaleo, M. Esteban and T. Calandra. 2009. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 5, e1000480
  • C. E. Gómez, J. L. Nájera, R. Sánchez, V. Jiménez and M. Esteban. 2009. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens. Vaccine 27, 3165-74
  • F. J. Chichón, M. J. Rodríguez, C. Risco, A. Fraile-Ramos, J. J. Fernández, M. Esteban and J. L. Carrascosa. 2009. Membrane remodeling during vaccinia virus morphogenesis. Biol Cell. 101, 401-14

2008

  • A. M. Vandermeeren, C. E. Gomez, C. Patiño, E. Domingo-Gil, S. Guerra, J. M. Gonzalez and M. Esteban. 2008. Subcellular forms and biochemical events triggered in human cells by HCV polyprotein expression from a viral vector. Virol J 5, 102
  • S. Guerra, A. Caceres, K. P. Knobeloch, I. Horak and M. Esteban. 2008. Vaccinia virus E3 protein prevents the antiviral action of ISG15. PLoS Pathog 4, e1000096
  • P. Mooij, S. S. Balla-Jhagjhoorsingh, G. Koopman, N. Beenhakker, P. van Haaften, I. Baak, I. G. Nieuwenhuis, I. Kondova, R. Wagner, H. Wolf, C. E. Gomez, J. L. Najera, V. Jimenez, M. Esteban and J. L. Heeney. 2008. Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J Virol 82, 2975-88
  • G. Kochan, D. Escors, J. M. Gonzalez, J. M. Casasnovas and M. Esteban. 2008. Membrane cell fusion activity of the vaccinia virus A17-A27 protein complex. Cell Microbiol 10, 149-164
  • A. Harari, P. A. Bart, W. Stohr, G. Tapia, M. Garcia, E. Medjitna-Rais, S. Burnet, C. Cellerai, O. Erlwein, T. Barber, C. Moog, P. Liljestrom, R. Wagner, H. Wolf, J. P. Kraehenbuhl, M. Esteban, J. Heeney, M. J. Frachette, J. Tartaglia, S. McCormack, A. Babiker, J. Weber and G. Pantaleo. 2008. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 205, 63-77
  • C. E. Gomez, J. L. Najera, M. Krupa and M. Esteban. 2008. The Poxvirus Vectors MVA and NYVAC as Gene Delivery Systems for Vaccination Against Infectious Diseases and Cancer. Curr Gene Ther 8, 97-120
  • B. Dondji, E. Deak, K. Goldsmith-Pestana, E. Perez-Jimenez, M. Esteban, S. Miyake, T. Yamamura and D. McMahon-Pratt. 2008. Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania. Eur J Immunol 38, 706-19
  • E. Domingo-Gil, E. Perez-Jimenez, I. Ventoso, J. L. Najera and M. Esteban. 2008. Expression of the E3L gene of vaccinia virus in transgenic mice decreases the host resistance to vaccinia virus and Leishmania major infection. J Virol 82, 254-267
  • M. Corbett, W. M. Bogers, J. L. Heeney, S. Gerber, C. Genin, A. Didierlaurent, H. Oostermeijer, R. Dubbes, G. Braskamp, S. Lerondel, C. E. Gomez, M. Esteban, R. Wagner, I. Kondova, P. Mooij, S. Balla-Jhagjhoorsingh, N. Beenhakker, G. Koopman, S. van der Burg, J. P. Kraehenbuhl and A. Le Pape. 2008. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic. Proc Natl Acad Sci U S A 105, 2046-51
  • P. A. Bart, R. Goodall, T. Barber, A. Harari, A. Guimaraes-Walker, M. Khonkarly, N. C. Sheppard, Y. Bangala, M. J. Frachette, R. Wagner, P. Liljestrom, J. P. Kraehenbuhl, M. Girard, J. Goudsmit, M. Esteban, J. Heeney, Q. Sattentau, S. McCormack, A. Babiker, G. Pantaleo and J. Weber. 2008. EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine 26, 3153-61

2007

  • M. Esteban. 2007. RNA interferente: del descubrimiento a sus aplicaciones. An. R. Acad. Nac. Farm. 73, 97-124
  • M. Esteban. 2007. Desarrollo de vacunas contra el VIH/SIDA. Academia de Farmacia de Galicia (discurso de toma de posesión como Académico correspondiente, 28 Marzo). An. R. Acad. Nac. Farm. 73, 1047-1078
  • M. Esteban. 2007. Interferones y vacunas como control de enfermedades prevalentes. En "Bioquímica y Fisiopatología del Sistema Immune", eds, María Cascales Angosto & Pedro García Barreno. Instituto de España. 245-301
  • M.A. Garcia, C. Muñoz-Fontela, M. Collado, L. Marcos-Villar, M. Esteban and C. Rivas. 2007. Novel and unexpected role for the tumor suppressor ARF in viral infection surveillance. Future Virology 2, 625-629
  • C. Muñoz-Fontela, M. A. Garcia, M. Collado, L. Marcos-Villar, P. Gallego, M. Esteban and C. Rivas. 2007. Control of virus infection by tumour suppressors. Carcinogenesis 28, 1140-4
  • S. Guerra, J. L. Najera, J. M. Gonzalez, L. A. Lopez-Fernandez, N. Climent, J. M. Gatell, T. Gallart and M. Esteban. 2007. Distinct Gene Expression Profiling after Infection of Immature Human Monocyte-Derived Dendritic Cells by the Attenuated Poxvirus Vectors MVA and NYVAC. J Virol 81, 8707-21
  • C. E. Gomez, J. L. Najera, V. Jimenez, K. Bieler, J. Wild, L. Kostic, S. Heidari, M. Chen, M. J. Frachette, G. Pantaleo, H. Wolf, P. Liljestrom, R. Wagner and M. Esteban. 2007. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine 25, 1969-92
  • C. E. Gomez, J. L. Najera, E. P. Jimenez, V. Jimenez, R. Wagner, M. Graf, M. J. Frachette, P. Liljestrom, G. Pantaleo and M. Esteban. 2007. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 25, 2863-85
  • C. E. Gomez, J. L. Najera, E. Domingo-Gil, L. Ochoa-Callejero, G. Gonzalez-Aseguinolaza and M. Esteban. 2007. Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. J Gen Virol 88, 2473-8
  • M. A. Garcia, E. F. Meurs and M. Esteban. 2007. The dsRNA protein kinase PKR: Virus and cell control. Biochimie 89, 799-811
  • A. Fraile-Ramos, A. Pelchen-Matthews, C. Risco, M. T. Rejas, V. C. Emery, A. F. Hassan-Walker, M. Esteban and M. Marsh. 2007. The ESCRT machinery is not required for human cytomegalovirus envelopment. Cell Microbiol 9, 2955-67

2006

  • M. Esteban. 2006. Poxviridae. En "Virus patógenos", Ed. L. Carrasco y J.M Almendral. HELICE, Madrid. Capítulo 12, pp 245-261
  • M. Esteban. 2006. Interferones y Vacunas como control de enfermedades prevalentes. Discurso de ingreso como Académico de Número en la Real Academia Nacional de Farmacia, 26 Enero. Ed. Realigraf, p1-86
  • J. L. Najera, C. E. Gomez, E. Domingo-Gil, M. M. Gherardi and M. Esteban. 2006. Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol 80, 6033-47
  • S. Guerra, L. A. Lopez-Fernandez, A. Pascual-Montano, J. L. Najera, A. Zaballos and M. Esteban. 2006. Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells. J Virol 80, 985-98
  • S. Guerra, L. A. Lopez-Fernandez, M. A. Garcia, A. Zaballos and M. Esteban. 2006. Human gene profiling in response to the active protein kinase, interferon-induced serine/threonine protein kinase (PKR), in infected cells. Involvement of the transcription factor ATF-3 IN PKR-induced apoptosis. J Biol Chem 281, 18734-45
  • M. A. Garcia, J. Gil, I. Ventoso, S. Guerra, E. Domingo, C. Rivas and M. Esteban. 2006. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev 70, 1032-60
  • F. Abaitua, J. R. Rodriguez, A. Garzon, D. Rodriguez and M. Esteban. 2006. Improving recombinant MVA immune responses: Potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Virus Res 116, 11-20

2005

  • C. Munoz-Fontela, M. Angel Garcia, I. Garcia-Cao, M. Collado, J. Arroyo, M. Esteban, M. Serrano and C. Rivas. 2005. Resistance to viral infection of super p53 mice. Oncogene 24, 3059-62
  • S. Guerra, M. Aracil, R. Conde, A. Bernad and M. Esteban. 2005. Wiskott-Aldrich syndrome protein is needed for vaccinia virus pathogenesis. J Virol 79, 2133-40
  • B. Gonzalez, R. Reina, I. Garcia, S. Andres, I. Glaria, M. Alzueta, M. I. Mora, B. M. Jugo, I. Arrieta-Aguirre, J. M. de la Lastra, D. Rodriguez, J. R. Rodriguez, M. Esteban, M. J. Grillo, B. A. Blacklaws, G. D. Harkiss, Y. Chebloune, L. Lujan, D. de Andres and B. Amorena. 2005. Mucosal immunization of sheep with a Maedi-Visna virus (MVV) env DNA vaccine protects against early MVV productive infection. Vaccine 23, 4342-52
  • C. E. Gomez, A. M. Vandermeeren, M. A. Garcia, E. Domingo-Gil and M. Esteban. 2005. Involvement of PKR and RNase L in translational control and induction of apoptosis after Hepatitis C polyprotein expression from a vaccinia virus recombinant. Virol J 2, 81
  • M. M. Gherardi and M. Esteban. 2005. Recombinant poxviruses as mucosal vaccine vectors. J Gen Virol 86, 2925-36
  • B. Dondji, E. Perez-Jimenez, K. Goldsmith-Pestana, M. Esteban and D. McMahon-Pratt. 2005. Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect Immun 73, 5286-9
  • M. Cyrklaff, C. Risco, J. J. Fernandez, M. V. Jimenez, M. Esteban, W. Baumeister and J. L. Carrascosa. 2005. Cryo-electron tomography of vaccinia virus. Proc Natl Acad Sci U S A 102, 2772-7
  • J. Alcami, J. Joseph Munne, M. A. Munoz-Fernandez and M. Esteban. 2005. [Present situation in the development of a preventive HIV vaccine.]. Enferm Infecc Microbiol Clin 23 Suppl 2, 5-14
  • J. Alcami, J. Joseph Munne, M. A. Munoz-Fernandez and M. Esteban. 2005. Current situation in the development of a preventive HIV vaccine. Enferm Infecc Microbiol Clin 23, 15-24

2004

  • S. Guerra, L. A. Lopez-Fernandez, R. Conde, A. Pascual-Montano, K. Harshman and M. Esteban. 2004. Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J Virol 78, 5820-34
  • C. E. Gomez, F. Abaitua, D. Rodriguez and M. Esteban. 2004. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma. Virus Res 105, 11-22
  • J. Gil, M. A. Garcia, P. Gomez-Puertas, S. Guerra, J. Rullas, H. Nakano, J. Alcami and M. Esteban. 2004. TRAF family proteins link PKR with NF-kappa B activation. Mol Cell Biol 24, 4502-12
  • J. Gil and M. Esteban. 2004. Vaccinia virus recombinants as a model system to analyze interferon-induced pathways. J Interferon Cytokine Res 24, 637-46
  • M. M. Gherardi, E. Perez-Jimenez, J. L. Najera and M. Esteban. 2004. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J Immunol 172, 6209-20
  • A. Didierlaurent, J. C. Ramirez, M. Gherardi, S. C. Zimmerli, M. Graf, H. A. Orbea, G. Pantaleo, R. Wagner, M. Esteban, J. P. Kraehenbuhl and J. C. Sirard. 2004. Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses. Vaccine 22, 3395-403

2003

  • E. Tapia, E. Perez-Jimenez, L. Lopez-Fuertes, R. Gonzalo, M. M. Gherardi and M. Esteban. 2003. The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK. Microbes Infect 5, 73-84
  • M. J. Ramiro, J. J. Zarate, T. Hanke, D. Rodriguez, J. R. Rodriguez, M. Esteban, J. Lucientes, J. A. Castillo and V. Larraga. 2003. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 21, 2474-84
  • J. C. Ramirez, D. Finke, M. Esteban, J. P. Kraehenbuhl and H. Acha-Orbea. 2003. Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration. Arch Virol 148, 827-39
  • S. Guerra, L. A. Lopez-Fernandez, A. Pascual-Montano, M. Munoz, K. Harshman and M. Esteban. 2003. Cellular gene expression survey of vaccinia virus infection of human HeLa cells. J Virol 77, 6493-506
  • C. Gonzalez-Lopez, J. Martinez-Costas, M. Esteban and J. Benavente. 2003. Evidence that avian reovirus sigmaA protein is an inhibitor of the double-stranded RNA-dependent protein kinase. J Gen Virol 84, 1629-39
  • G. Gonzalez-Aseguinolaza, Y. Nakaya, A. Molano, E. Dy, M. Esteban, D. Rodriguez, J. R. Rodriguez, P. Palese, A. Garcia-Sastre and R. S. Nussenzweig. 2003. Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium yoelii. J Virol 77, 11859-66
  • M. M. Gherardi, J. C. Ramirez and M. Esteban. 2003. IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system. J Gen Virol 84, 1961-72
  • M. M. Gherardi, J. L. Najera, E. Perez-Jimenez, S. Guerra, A. Garcia-Sastre and M. Esteban. 2003. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes. J Virol 77, 7048-57
  • J. C. Gallego-Gomez, C. Risco, D. Rodriguez, P. Cabezas, S. Guerra, J. L. Carrascosa and M. Esteban. 2003. Differences in Virus-Induced Cell Morphology and in Virus Maturation between MVA and Other Strains (WR, Ankara, and NYCBH) of Vaccinia Virus in Infected Human Cells. J Virol 77, 10606-22
  • M. Esteban, M. A. Garcia, E. Domingo-Gil, J. Arroyo, C. Nombela and C. Rivas. 2003. The latency protein LANA2 from Kaposi's sarcoma-associated herpesvirus inhibits apoptosis induced by dsRNA-activated protein kinase but not RNase L activation. J Gen Virol 84, 1463-70

2002

  • A. B. Sanchez, D. Rodriguez, A. Garzon, B. Amorena, M. Esteban and J. R. Rodriguez. 2002. Visna/maedi virus Env protein expressed by a vaccinia virus recombinant induces cell-to-cell fusion in cells of different origins in the apparent absence of Env cleavage: role of glycosylation and of proteoglycans. Arch Virol 147, 2377-92
  • C. Risco, J. R. Rodriguez, C. Lopez-Iglesias, J. L. Carrascosa, M. Esteban and D. Rodriguez. 2002. Endoplasmic reticulum-Golgi intermediate compartment membranes and vimentin filaments participate in vaccinia virus assembly. J Virol 76, 1839-55
  • J. C. Ramirez, E. Tapia and M. Esteban. 2002. Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions. J Gen Virol 83, 1059-67
  • L. Lopez-Fuertes, E. Perez-Jimenez, A. J. Vila-Coro, F. Sack, S. Moreno, S. A. Konig, C. Junghans, B. Wittig, M. Timon and M. Esteban. 2002. DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine 21, 247-57
  • Z. Humlova, M. Vokurka, M. Esteban and Z. Melkova. 2002. Vaccinia virus induces apoptosis of infected macrophages. J Gen Virol 83, 2821-32
  • R. M. Gonzalo, G. del Real, J. R. Rodriguez, D. Rodriguez, R. Heljasvaara, P. Lucas, V. Larraga and M. Esteban. 2002. A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine 20, 1226-31
  • C. E. Gomez, D. Rodriguez, J. R. Rodriguez, F. Abaitua, C. Duarte and M. Esteban. 2002. Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector. Vaccine 20, 961-71
  • J. Gil, M. A. Garcia and M. Esteban. 2002. Caspase 9 activation by the dsRNA-dependent protein kinase, PKR: molecular mechanism and relevance. FEBS Lett 529, 249-55
  • M. A. Garcia, S. Guerra, J. Gil, V. Jimenez and M. Esteban. 2002. Anti-apoptotic and oncogenic properties of the dsRNA-binding protein of vaccinia virus, E3L. Oncogene 21, 8379-87
  • M. Agromayor, P. Ortiz, J. L. Lopez-Estebaranz, J. Gonzalez-Nicolas, M. Esteban and A. Martin-Gallardo. 2002. Molecular epidemiology of molluscum contagiosum virus and analysis of the host-serum antibody response in Spanish HIV-negative patients. J Med Virol 66, 151-8

2001

  • F. Zavala, M. Rodrigues, D. Rodriguez, J. R. Rodriguez, R. S. Nussenzweig and M. Esteban. 2001. A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8(+) T cells. Virology 280, 155-9
  • K. Wallengren, C. Risco, J. Krijnse-Locker, M. Esteban and D. Rodriguez. 2001. The A17L gene product of vaccinia virus is exposed on the surface of IMV. Virology 290, 143-52
  • R. Heljasvaara, D. Rodriguez, C. Risco, J. L. Carrascosa, M. Esteban and J. R. Rodriguez. 2001. The major core protein P4a (A10L gene) of vaccinia virus is essential for correct assembly of viral DNA into the nucleoprotein complex to form immature viral particles. J Virol 75, 5778-95
  • R. M. Gonzalo, J. R. Rodriguez, D. Rodriguez, G. Gonzalez-Aseguinolaza, V. Larraga and M. Esteban. 2001. Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36. Microbes Infect 3, 701-11
  • C. E. Gomez and M. Esteban. 2001. Recombinant proteins produced by vaccinia virus vectors can be incorporated within the virion (IMV form) into different compartments. Arch Virol 146, 875-92
  • J. Gil, J. Rullas, M. A. Garcia, J. Alcami and M. Esteban. 2001. The catalytic activity of dsRNA-dependent protein kinase, PKR, is required for NF-kappaB activation. Oncogene 20, 385-94
  • J. Gil, J. Rullas, J. Alcami and M. Esteban. 2001. MC159L protein from the poxvirus molluscum contagiosum virus inhibits NF-kappaB activation and apoptosis induced by PKR. J Gen Virol 82, 3027-34
  • J. Gil and M. Esteban 2001. Antiviral role of the dsRNA-dependent protein kinase, PKR. Recent Res. Devel. Virol. 3, 13-27
  • M. M. Gherardi, J. C. Ramirez and M. Esteban. 2001. Towards a new generation of vaccines: the cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens. Histol Histopathol 16, 655-67

2000

  • J. C. Ramirez, M. M. Gherardi, D. Rodriguez and M. Esteban. 2000. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol 74, 7651-5
  • J. C. Ramirez, M. M. Gherardi and M. Esteban. 2000. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 74, 923-33
  • J. Oliveira-Ferreira, Y. Myahira, G. T. Layton, N. Savage, M. Esteban, D. Rodriguez, J. R. Rodriguez, R. S. Nussenzweig and F. Zavala. 2000. Immunogenicity of Ty-VLP bearing a CD8(+) T cell epitope of the CS protein of P. yoelii: enhanced memory response by boosting with recombinant vaccinia virus. Vaccine 18, 2923
  • J. Gil, M. Esteban and D. Roth. 2000. In vivo regulation of protein synthesis by phosphorylation of the alpha subunit of wheat eukaryotic initiation factor 2. Biochemistry 39, 7521-30
  • J. Gil, M. Esteban and D. Roth. 2000. In vivo regulation of the dsRNA-dependent protein kinase PKR by the cellular glycoprotein p67. Biochemistry 39, 16016-25
  • J. Gil and M. Esteban. 2000. The interferon-induced protein kinase (PKR), triggers apoptosis through FADD-mediated activation of caspase 8 in a manner independent of Fas and TNF-alpha receptors. Oncogene 19, 3665-74
  • J. Gil and M. Esteban. 2000. Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): mechanism of action. Apoptosis 5, 107-14
  • J. Gil, J. Alcami and M. Esteban. 2000. Activation of NF-kappa B by the dsRNA-dependent protein kinase, PKR involves the I kappa B kinase complex. Oncogene 19, 1369-78
  • M. M. Gherardi, J. C. Ramirez and M. Esteban. 2000. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide. J Virol 74, 6278-86
  • M. Esteban and C. Patiño. 2000. Identification by electron microscopy of the maturation steps in vaccinia virus morphogenesis inhibited by the interferon-induced enzymes, protein kinase (PKR), 2-5A synthetase, and nitric oxide synthase (iNOS). J Interferon Cytokine Res 20, 867-77
  • M. Collado, D. Rodriguez, J. R. Rodriguez, I. Vazquez, R. M. Gonzalo and M. Esteban. 2000. Chimeras between the human immunodeficiency virus (HIV-1) Env and vaccinia virus immunogenic proteins p14 and p39 generate in mice broadly reactive antibodies and specific activation of CD8+ T cell responses to Env. Vaccine 18, 3123-33

1999

  • M. I. Vazquez and M. Esteban. 1999. Identification of functional domains in the 14-kilodalton envelope protein (A27L) of vaccinia virus. J Virol 73, 9098-109
  • D. Rodriguez, J. R. Rodriguez, M. Llorente, I. Vazquez, P. Lucas, M. Esteban, A. C. Martinez and G. del Real. 1999. A human immunodeficiency virus type 1 Env-granulocyte-macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine. J Gen Virol 80 ( Pt 1), 217-23
  • D. Rodriguez, Rodriguez, J.R., Llorente, M., Lucas, P., Esteban, M., Martinez-A, C., del Real, G. 1999. Use of DNA priming and Vaccinia virus boosting to trigger an efficient immune response to HIV-1 gp120. Gene Therapy and Molecular Biology 3, 179-187
  • C. Rivas, J. Gil and M. Esteban. 1999. Identification of functional domains of the interferon-induced enzyme PKR in cells lacking endogenous PKR. J Interferon Cytokine Res 19, 1229-36
  • C. Risco, J. R. Rodriguez, W. Demkowicz, R. Heljasvaara, J. L. Carrascosa, M. Esteban and D. Rodriguez. 1999. The vaccinia virus 39-kDa protein forms a stable complex with the p4a/4a major core protein early in morphogenesis. Virology 265, 375-86
  • M. Pavon and M. Esteban. 1999. Identification by two-dimensional gel electrophoresis of vaccinia virus and cellular phosphoproteins modified after inducible expression of the dsRNA-activated protein kinase. J Interferon Cytokine Res 19, 589-99
  • R. M. Gonzalo, D. Rodriguez, A. Garcia-Sastre, J. R. Rodriguez, P. Palese and M. Esteban. 1999. Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants. Vaccine 17, 887-92
  • J. Gil, J. Alcami and M. Esteban. 1999. Induction of apoptosis by double-stranded-RNA-dependent protein kinase (PKR) involves the alpha subunit of eukaryotic translation initiation factor 2 and NF-kappaB. Mol Cell Biol 19, 4653-63
  • M. M. Gherardi, J. C. Ramirez, D. Rodriguez, J. R. Rodriguez, G. Sano, F. Zavala and M. Esteban. 1999. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner. J Immunol 162, 6724-33
  • M. M. Gherardi and M. Esteban. 1999. Mucosal and systemic immune responses induced after oral delivery of vaccinia virus recombinants. Vaccine 17, 1074-83
  • M. Diaz-Guerra, C. Rivas and M. Esteban. 1999. Full activation of RNaseL in animal cells requires binding of 2-5A within ankyrin repeats 6 to 9 of this interferon-inducible enzyme. J Interferon Cytokine Res 19, 113-9

1998

  • M. I. Vazquez, G. Rivas, D. Cregut, L. Serrano and M. Esteban. 1998. The vaccinia virus 14-kilodalton (A27L) fusion protein forms a triple coiled-coil structure and interacts with the 21-kilodalton (A17L) virus membrane protein through a C-terminal alpha-helix. J Virol 72, 10126-37
  • J. R. Rodriguez, C. Risco, J. L. Carrascosa, M. Esteban and D. Rodriguez. 1998. Vaccinia virus 15-kilodalton (A14L) protein is essential for assembly and attachment of viral crescents to virosomes. J Virol 72, 1287-96
  • C. Rivas, J. Gil, Z. Melkova, M. Esteban and M. Diaz-Guerra. 1998. Vaccinia virus E3L protein is an inhibitor of the interferon (i.f.n.)-induced 2-5A synthetase enzyme. Virology 243, 406-14
  • Y. Miyahira, A. Garcia-Sastre, D. Rodriguez, J. R. Rodriguez, K. Murata, M. Tsuji, P. Palese, M. Esteban, F. Zavala and R. S. Nussenzweig. 1998. Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice. Proc Natl Acad Sci U S A 95, 3954-9

1997

  • T. Salmons, A. Kuhn, F. Wylie, S. Schleich, J. R. Rodriguez, D. Rodriguez, M. Esteban, G. Griffiths and J. K. Locker. 1997. Vaccinia virus membrane proteins p8 and p16 are cotranslationally inserted into the rough endoplasmic reticulum and retained in the intermediate compartment. J Virol 71, 7404-20
  • J. R. Rodriguez, C. Risco, J. L. Carrascosa, M. Esteban and D. Rodriguez. 1997. Characterization of early stages in vaccinia virus membrane biogenesis: implications of the 21-kilodalton protein and a newly identified 15-kilodalton envelope protein. J Virol 71, 1821-33
  • M. Moratilla, M. Agromayor, A. Nunez, J. M. Funes, A. J. Varas, J. L. Lopez-Estebaranz, M. Esteban and A. Martin-Gallardo. 1997. A random DNA sequencing, computer-based approach for the generation of a gene map of molluscum contagiosum virus. Virus Genes 14, 73-80
  • Z. Melkova, S. B. Lee, D. Rodriguez and M. Esteban. 1997. Bcl-2 prevents nitric oxide-mediated apoptosis and poly(ADP-ribose) polymerase cleavage. FEBS Lett 403, 273-8
  • S. B. Lee, D. Rodriguez, J. R. Rodriguez and M. Esteban. 1997. The apoptosis pathway triggered by the interferon-induced protein kinase PKR requires the third basic domain, initiates upstream of Bcl-2, and involves ICE-like proteases. Virology 231, 81-8
  • M. Diaz-Guerra, C. Rivas and M. Esteban. 1997. Inducible expression of the 2-5A synthetase/RNase L system results in inhibition of vaccinia virus replication. Virology 227, 220-8
  • M. Diaz-Guerra, C. Rivas and M. Esteban. 1997. Activation of the IFN-inducible enzyme RNase L causes apoptosis of animal cells. Virology 236, 354-63
  • M. Diaz-Guerra, M. Esteban and J. L. Martinez. 1997. Growth of Escherichia coli in acetate as a sole carbon source is inhibited by ankyrin-like repeats present in the 2',5'-linked oligoadenylate-dependent human RNase L enzyme. FEMS Microbiol Lett 149, 107-13

1996

  • D. R. Taylor, S. B. Lee, P. R. Romano, D. R. Marshak, A. G. Hinnebusch, M. Esteban and M. B. Mathews. 1996. Autophosphorylation sites participate in the activation of the double-stranded-RNA-activated protein kinase PKR. Mol Cell Biol 16, 6295-302
  • P. Suarez, M. Diaz-Guerra, C. Prieto, M. Esteban, J. M. Castro, A. Nieto and J. Ortin. 1996. Open reading frame 5 of porcine reproductive and respiratory syndrome virus as a cause of virus-induced apoptosis. J Virol 70, 2876-82
  • D. Rodriguez, C. Risco, J. R. Rodriguez, J. L. Carrascosa and M. Esteban. 1996. Inducible expression of the vaccinia virus A17L gene provides a synchronized system to monitor sorting of viral proteins during morphogenesis. J Virol 70, 7641-53
  • A. Nunez, J. M. Funes, M. Agromayor, M. Moratilla, A. J. Varas, J. L. Lopez-Estebaranz, M. Esteban and A. Martin-Gallardo. 1996. Detection and typing of molluscum contagiosum virus in skin lesions by using a simple lysis method and polymerase chain reaction. J Med Virol 50, 342-9
  • K. Murata, A. Garcia-Sastre, M. Tsuji, M. Rodrigues, D. Rodriguez, J. R. Rodriguez, R. S. Nussenzweig, P. Palese, M. Esteban and F. Zavala. 1996. Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. Cell Immunol 173, 96-107
  • A. Martin-Gallardo, M. Moratilla, J. M. Funes, M. Agromayor, A. Nunez, A. J. Varas, M. Collado, A. Valencia, J. L. Lopez-Estebaranz and M. Esteban. 1996. Sequence analysis of a Molluscum contagiosum virus DNA region which includes the gene encoding protein kinase 2 and other genes with unique organization. Virus Genes 13, 19-29
  • S. B. Lee, R. Bablanian and M. Esteban. 1996. Regulated expression of the interferon-induced protein kinase p68 (PKR) by vaccinia virus recombinants inhibits the replication of vesicular stomatitis virus but not that of poliovirus. J Interferon Cytokine Res 16, 1073-8
  • M. Esteban, J. Ramon Rodriguez, V. Jimenez and D. Rodriguez. 1996. Use of persistent infections with vaccinia virus recombinants to introduce alterations in foreign proteins: an application to HIV-1 env protein. Virus Res 46, 45-56
  • S. Cudmore, R. Blasco, R. Vincentelli, M. Esteban, B. Sodeik, G. Griffiths and J. Krijnse Locker. 1996. A vaccinia virus core protein, p39, is membrane associated. J Virol 70, 6909-21
  • A. Brun, C. Rivas, M. Esteban, J. M. Escribano and C. Alonso. 1996. African swine fever virus gene A179L, a viral homologue of bcl-2, protects cells from programmed cell death. Virology 225, 227-30

1995

  • B. Sodeik, S. Cudmore, M. Ericsson, M. Esteban, E. G. Niles and G. Griffiths. 1995. Assembly of vaccinia virus: incorporation of p14 and p32 into the membrane of the intracellular mature virus. J Virol 69, 3560-74
  • D. Rodriguez, J. R. Rodriguez and M. Esteban. 1995. Enhanced proteolytic processing of the human immunodeficiency virus type 1 envelope protein in murine Ltk(-) cells. AIDS Res Hum Retroviruses 11, 81-5
  • D. Rodriguez, M. Esteban and J. R. Rodriguez. 1995. Vaccinia virus A17L gene product is essential for an early step in virion morphogenesis. J Virol 69, 4640-8
  • Y. Miyahira, K. Murata, D. Rodriguez, J. R. Rodriguez, M. Esteban, M. M. Rodrigues and F. Zavala. 1995. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J Immunol Methods 181, 45-54
  • Z. Melkova and M. Esteban. 1995. Inhibition of vaccinia virus DNA replication by inducible expression of nitric oxide synthase. J Immunol 155, 5711-8

1994

  • M. Rodrigues, S. Li, K. Murata, D. Rodriguez, J. R. Rodriguez, I. Bacik, J. R. Bennink, J. W. Yewdell, A. Garcia-Sastre, R. S. Nussenzweig, M. Esteban, P. Palese and F. Zavala. 1994. Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. J Immunol 153, 4636-48
  • Z. Melkova and M. Esteban. 1994. Interferon-gamma severely inhibits DNA synthesis of vaccinia virus in a macrophage cell line. Virology 198, 731-5
  • S. B. Lee, S. R. Green, M. B. Mathews and M. Esteban. 1994. Activation of the double-stranded RNA (dsRNA)-activated human protein kinase in vivo in the absence of its dsRNA binding domain. Proc Natl Acad Sci U S A 91, 10551-5
  • S. B. Lee and M. Esteban. 1994. The interferon-induced double-stranded RNA-activated protein kinase induces apoptosis. Virology 199, 491-6

1993

  • D. Rodriguez, J. R. Rodriguez and M. Esteban. 1993. The vaccinia virus 14-kilodalton fusion protein forms a stable complex with the processed protein encoded by the vaccinia virus A17L gene. J Virol 67, 3435-40
  • D. McMahon-Pratt, D. Rodriguez, J. R. Rodriguez, Y. Zhang, K. Manson, C. Bergman, L. Rivas, J. F. Rodriguez, K. L. Lohman, N. H. Ruddle and Mariano Esteban. 1993. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection. Infect Immun 61, 3351-9
  • S. Li, M. Rodrigues, D. Rodriguez, J. R. Rodriguez, M. Esteban, P. Palese, R. S. Nussenzweig and F. Zavala. 1993. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci U S A 90, 5214-8
  • S. B. Lee, Z. Melkova, W. Yan, B. R. Williams, A. G. Hovanessian and M. Esteban. 1993. The interferon-induced double-stranded RNA-activated human p68 protein kinase potently inhibits protein synthesis in cultured cells. Virology 192, 380-5
  • S. B. Lee and M. Esteban. 1993. The interferon-induced double-stranded RNA-activated human p68 protein kinase inhibits the replication of vaccinia virus. Virology 193, 1037-41
  • M. Diaz-Guerra, J. S. Kahn and M. Esteban. 1993. A mutation of the nucleoside triphosphate phosphohydrolase I (NPH-I) gene confers sensitivity of vaccinia virus to interferon. Virology 197, 485-91
  • M. Diaz-Guerra and M. Esteban. 1993. Vaccinia virus nucleoside triphosphate phosphohydrolase I controls early and late gene expression by regulating the rate of transcription. J Virol 67, 7561-72
  • R. Bablanian, S. Scribani and M. Esteban. 1993. Amplification of polyadenylated nontranslated small RNA sequences (POLADS) during superinfection correlates with the inhibition of viral and cellular protein synthesis. Cell Mol Biol Res 39, 243-55

1992

  • J. R. Rodriguez, D. Rodriguez and M. Esteban. 1992. Insertional inactivation of the vaccinia virus 32-kilodalton gene is associated with attenuation in mice and reduction of viral gene expression in polarized epithelial cells. J Virol 66, 183-9
  • W. E. Demkowicz, J. S. Maa and M. Esteban. 1992. Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans. J Virol 66, 386-98

1991

  • J. R. Rodriguez, D. Rodriguez and M. Esteban. 1991. Structural properties of HIV-1 Env fused with the 14-kDa vaccinia virus envelope protein. Virology 181, 742-8
  • J. R. Rodriguez, D. Rodriguez and M. Esteban. 1991. Interferon treatment inhibits early events in vaccinia virus gene expression in infected mice. Virology 185, 929-33
  • D. Rodriguez, J. R. Rodriguez, G. K. Ojakian and M. Esteban. 1991. Vaccinia virus preferentially enters polarized epithelial cells through the basolateral surface. J Virol 65, 494-8
  • C. F. Lai, S. C. Gong and M. Esteban. 1991. The 32-kilodalton envelope protein of vaccinia virus synthesized in Escherichia coli binds with specificity to cell surfaces. J Virol 65, 499-504
  • C. F. Lai, S. C. Gong and M. Esteban. 1991. The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals. J Virol 65, 5631-5
  • R. Bablanian, S. K. Goswami, M. Esteban, A. K. Banerjee and W. C. Merrick. 1991. Mechanism of selective translation of vaccinia virus mRNAs: differential role of poly(A) and initiation factors in the translation of viral and cellular mRNAs. J Virol 65, 4449-60

1990

  • D. Rodriguez, Y. W. Zhou, J. R. Rodriguez, R. K. Durbin, V. Jimenez, W. T. McAllister and M. Esteban. 1990. Regulated expression of nuclear genes by T3 RNA polymerase and lac repressor, using recombinant vaccinia virus vectors. J Virol 64, 4851-7
  • J. S. Maa, J. F. Rodriguez and M. Esteban. 1990. Structural and functional characterization of a cell surface binding protein of vaccinia virus. J Biol Chem 265, 1569-77
  • C. F. Lai, S. C. Gong and M. Esteban. 1990. Structural and functional properties of the 14-kDa envelope protein of vaccinia virus synthesized in Escherichia coli. J Biol Chem 265, 22174-80
  • J. S. Kahn and M. Esteban. 1990. Identification of the point mutations in two vaccinia virus nucleoside triphosphate phosphohydrolase I temperature-sensitive mutants and role of this DNA-dependent ATPase enzyme in virus gene expression. Virology 174, 459-71
  • S. C. Gong, C. F. Lai and M. Esteban. 1990. Vaccinia virus induces cell fusion at acid pH and this activity is mediated by the N-terminus of the 14-kDa virus envelope protein. Virology 178, 81-91

1989

  • J. F. Rodriguez and M. Esteban. 1989. Plaque size phenotype as a selectable marker to generate vaccinia virus recombinants. J Virol 63, 997-1001
  • D. Rodriguez, J. R. Rodriguez, J. F. Rodriguez, D. Trauber and M. Esteban. 1989. Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses. Proc Natl Acad Sci U S A 86, 1287-91
  • A. Portela, Rodriguez, J.R., Rodriguez, D., Rodriguez, F., Garcia-Barreno, B., Melero, J.A. and Esteban, M. 1989. Expression of the fusion (F) protein of human respiratory syncytial virus using an attenuated strain of vaccinia virus. Genetics and Pathogenicity of Negative Strand Viruses.
  • S. C. Gong, C. F. Lai, S. Dallo and M. Esteban. 1989. A single point mutation of Ala-25 to Asp in the 14,000-Mr envelope protein of vaccinia virus induces a size change that leads to the small plaque size phenotype of the virus. J Virol 63, 4507-14
  • S. Dallo, J. S. Maa, J. R. Rodriguez, D. Rodriguez and M. Esteban. 1989. Humoral immune response elicited by highly attenuated variants of vaccinia virus and by an attenuated recombinant expressing HIV-1 envelope protein. Virology 173, 323-9

1988

  • J. F. Rodriguez, D. Rodriguez, J. R. Rodriguez, E. B. McGowan and M. Esteban. 1988. Expression of the firefly luciferase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals. Proc Natl Acad Sci U S A 85, 1667-71
  • E. Paez and M. Esteban. 1988. Stability of vaccinia virus DNA during persistent infections: accumulation of left-end deletions and of tandem repeats at both ends of the viral genome and prevention by interferon. Virology 163, 145-54
  • E. Feduchi, M. Esteban and L. Carrasco. 1988. Reovirus type 3 synthesizes proteins in interferon-treated HeLa cells without reversing the antiviral state. Virology 164, 420-6

1987

  • G. Zavagno, B. Jaffe and M. Esteban. 1987. Role of prostaglandins and non-steroid anti-inflammatory drugs in the pathogenicity of vaccinia virus. J Gen Virol 68 ( Pt 2), 593-600
  • J. F. Rodriguez, E. Paez and M. Esteban. 1987. A 14,000-Mr envelope protein of vaccinia virus is involved in cell fusion and forms covalently linked trimers. J Virol 61, 395-404
  • J. F. Rodriguez and M. Esteban. 1987. Mapping and nucleotide sequence of the vaccinia virus gene that encodes a 14-kilodalton fusion protein. J Virol 61, 3550-4
  • E. Paez and M. Esteban. 1987. Resistance of vaccinia virus to interferons: modulation of the 2-5A system in interferon-treated, vaccinia virus infected cells. Microbiologia 3, 163-78
  • E. Paez, S. Dallo and M. Esteban. 1987. Virus attenuation and identification of structural proteins of vaccinia virus that are selectively modified during virus persistence. J Virol 61, 2642-7
  • J. S. Maa and M. Esteban. 1987. Structural and functional studies of a 39,000-Mr immunodominant protein of vaccinia virus. J Virol 61, 3910-9
  • R. A. Janeczko, J. F. Rodriguez and M. Esteban. 1987. Studies on the mechanism of entry of vaccinia virus in animal cells. Arch Virol 92, 135-50
  • S. Dallo, J. F. Rodriguez and M. Esteban. 1987. A 14K envelope protein of vaccinia virus with an important role in virus-host cell interactions is altered during virus persistence and determines the plaque size phenotype of the virus. Virology 159, 423-32
  • S. Dallo and M. Esteban. 1987. Isolation and characterization of attenuated mutants of vaccinia virus. Virology 159, 408-22
  • R. Bablanian, S. K. Goswami, M. Esteban and A. K. Banerjee. 1987. Selective inhibition of protein synthesis by synthetic and vaccinia virus-core synthesized poly(riboadenylic acids). Virology 161, 366-73

1986

1985

  • J. F. Rodriguez, R. Janeczko and M. Esteban. 1985. Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus. J Virol 56, 482-8
  • M. Perucho and M. Esteban. 1985. Inhibitory effect of interferon on the genetic and oncogenic transformation by viral and cellular genes. J Virol 54, 229-32
  • E. Paez and M. Esteban. 1985. Interferon inhibits marker rescue of vaccinia virus. J Interferon Res 5, 247-56
  • E. Paez and M. Esteban. 1985. Interferon prevents the generation of spontaneous deletions at the left terminus of vaccinia virus DNA. J Virol 56, 75-84
  • E. Paez, S. Dallo and M. Esteban. 1985. Generation of a dominant 8-MDa deletion at the left terminus of vaccinia virus DNA. Proc Natl Acad Sci U S A 82, 3365-9
  • M. Esteban and E. Paez. 1985. Antiviral and antiproliferative properties of interferons: mechanism of action. Prog Med Virol 32, 159-73
  • M. Esteban and E. Paez. 1985. The 2-5A system and vaccinia virus. Prog Clin Biol Res 202, 25-34
  • M. Esteban, C. V. Cabrera and J. A. Holowczak. 1985. Biochemical and electron microscopic studies of the transcription of vaccinia DNA by RNA polymerase from Escherichia coli: localization and characterization of transcriptional complexes. J Virol Methods 12, 111-33

1984

  • E. Paez and M. Esteban. 1984. Resistance of vaccinia virus to interferon is related to an interference phenomenon between the virus and the interferon system. Virology 134, 12-28
  • E. Paez and M. Esteban. 1984. Nature and mode of action of vaccinia virus products that block activation of the interferon-mediated ppp(A2'p)nA-synthetase. Virology 134, 29-39
  • J. A. Lewis and M. Esteban. 1984. Induction of an anti-viral response and 2',5'-oligo A synthetase by interferon in several thymidine kinase-deficient cell lines. Virology 133, 464-9
  • M. Esteban, J. Benavente and E. Paez. 1984. Effect of interferon on integrity of vaccinia virus and ribosomal RNA in infected cells. Virology 134, 40-51
  • M. Esteban. 1984. Analysis of replicating vaccinia DNA in interferon-treated, virus-infected cells. J Interferon Res 4, 179-92
  • M. Esteban. 1984. Defective vaccinia virus particles in interferon-treated infected cells. Virology 133, 220-7
  • C. Boni, M. Esteban and A. Pellicer. 1984. Expression of cloned vaccinia virus DNA sequences introduced into animal cells. J Gen Virol 65 ( Pt 7), 1245-51
  • J. Benavente, E. Paez and M. Esteban. 1984. Indiscriminate degradation of RNAs in interferon-treated, vaccinia virus-infected mouse L cells. J Virol 51, 866-71
  • J. Benavente, M. Esteban, B. M. Jaffe and M. G. Santoro. 1984. Selective inhibition of viral gene expression as the mechanism of the antiviral action of PGA1 in vaccinia virus-infected cells. J Gen Virol 65 ( Pt 3), 599-608

1983

  • M. G. Santoro, B. M. Jaffe, E. Paez and M. Esteban. 1983. The relationship between the antiviral action of interferon and prostaglandins in virus-infected murine cells. Biochem Biophys Res Commun 116, 442-8
  • M. G. Santoro, B. M. Jaffe and M. Esteban. 1983. Prostaglandin A inhibits the replication of vesicular stomatitis virus: effect on virus glycoprotein. J Gen Virol 64 ( Pt 12), 2797-801
  • E. Mengheri, M. Esteban and J. A. Lewis. 1983. Thymidine kinase genes and the induction of anti-viral responses by interferon. FEBS Lett 157, 301-5
  • J. A. Lewis, E. Mengheri and M. Esteban. 1983. Induction of an antiviral response by interferon requires thymidine kinase. Proc Natl Acad Sci U S A 80, 26-30
  • M. Esteban, C. V. Cabrera and J. A. Holowczak. 1983. Electron microscopic studies of transcriptional complexes released from vaccinia cores during RNA-synthesis in vitro: methods for fractionation of transcriptional complexes. J Virol Methods 7, 73-92

1982

  • M. G. Santoro, B. M. Jaffe, E. Garaci and M. Esteban. 1982. Antiviral effect of prostaglandins of the A series: inhibition of vaccinia virus replication in cultured cells. J Gen Virol 63, 435-40
  • A. Pellicer and M. Esteban. 1982. Gene-transfer, stability, and biochemical properties of animal cells transformed with vaccinia DNA. Virology 122, 363-80
  • L. Carrasco and M. Esteban. 1982. Modification of membrane permeability in vaccinia virus-infected cells. Virology 117, 62-9

1981

  • R. Bablanian, G. Coppola, S. Scribani and M. Esteban. 1981. Inhibition of protein synthesis by vaccinia virus. III. The effect of ultraviolet-irradiated virus on the inhibition of protein synthesis. Virology 112, 1-12
  • R. Bablanian, G. Coppola, S. Scribani and M. Esteban. 1981. Inhibition of protein synthesis by vaccinia virus. IV. The role of low-molecular-weight viral RNA in the inhibition of protein synthesis. Virology 112, 13-24

1979

  • M. J. Soloski, C. V. Cabrera, M. Esteban and J. A. Holowczak. 1979. Studies concerning the structure and organization of the vaccinia virus nucleoid. I. Isolation and characterization of subviral particles prepared by treating virions with guanidine-HCL, nonidet-P40, and 2-mercaptoethanol. Virology 99, 209-17
  • M. Esteban, M. Soloski, C. V. Cabrera and J. A. Holowczak. 1979. Replication of vaccinia DNA and studies on the structure of the viral chromosome. Cold Spring Harb Symp Quant Biol 43 Pt 2, 789-99

1978

  • M. J. Soloski, M. Esteban and J. A. Holowczak. 1978. DNA-binding proteins in the cytoplasm of vaccinia virus-infected mouse L-cells. J Virol 25, 263-73
  • R. J. McCarron, C. V. Cabrera, M. Esteban, W. T. McAllister and J. A. Holowczak. 1978. Structure of vaccinia DNA: analysis of the viral genome by restriction endonucleases. Virology 86, 88-101
  • M. Esteban and J. A. Holowczak. 1978. Replication of vaccinia DNA in mouse L cells. IV. Protein synthesis and viral DNA replication. Virology 86, 376-90
  • C. V. Cabrera, M. Esteban, R. McCarron, W. T. McAllister and J. A. Holowczak. 1978. Vaccinia virus transcription: hybridization of mRNA to restriction fragments of vaccinia DNA. Virology 86, 102-14
  • C. V. Cabrera and M. Esteban. 1978. Procedure for purification of intact DNA from vaccinia virus. J Virol 25, 442-5
  • R. Bablanian, M. Esteban, B. Baxt and J. A. Sonnabend. 1978. Studies on the mechanisms of vaccina virus cytopathic effects. I. Inhibition of protein synthesis in infected cells is associated with virus-induced RNA synthesis. J Gen Virol 39, 391-402
  • R. Bablanian, B. Baxt, J. A. Sonnabend and M. Esteban. 1978. Studies on the mechanisms of vaccinia virus cytopathic effects. II. Early cell rounding is associated with virus polypeptide synthesis. J Gen Virol 39, 403-13

1977

  • M. Esteban and J. A. Holowczak. 1977. Replication of vaccinia DNA in mouse L cells. I. In vivo DNA synthesis. Virology 78, 57-75
  • M. Esteban and J. A. Holowczak. 1977. Replication of vaccinia DNA in mouse L cells. II. In vitro DNA synthesis in cytoplasmic extracts. Virology 78, 76-86
  • M. Esteban and J. A. Holowczak. 1977. Replication of vaccinia DNA in mouse L cells. III. Intracellular forms of viral DNA. Virology 82, 308-22
  • M. Esteban, L. Flores and J. A. Holowczak. 1977. Topography of vaccinia virus DNA. Virology 82, 163-81
  • M. Esteban, L. Flores and J. A. Holowczak. 1977. Model for vaccinia virus DNA replication. Virology 83, 467-73
  • M. Esteban. 1977. Rifampin and vaccinia DNA. J Virol 21, 796-801

1975

  • D. H. Metz, M. Esteban and G. Danielescu. 1975. The effect of interferon on the formation of virus polyribosomes in L cells infected with vaccinia virus. J Gen Virol 27, 197-209
  • D. H. Metz, M. Esteban and G. Danielescu. 1975. The formation of virus polyribosomes in L cells infected with vaccinia virus. J Gen Virol 27, 181-95

1974

  • M. Esteban and I. M. Kerr. 1974. The synthesis of encephalomyocarditis virus polypeptides in infected L-cells and cell-free systems. Eur J Biochem 45, 567-76

1973

1972

  • D. H. Metz and M. Esteban. 1972. Interferon inhibits viral protein synthesis in L cells infected with vaccinia virus. Nature 238, 385-8
  • R. M. Friedman, D. H. Metz, R. M. Esteban, D. R. Tovell, L. A. Ball and I. M. Kerr. 1972. Mechanism of interferon action: inhibition of viral messenger ribonucleic acid translation in L-cell extracts. J Virol 10, 1184-98
  • R. M. Friedman, R. M. Esteban, D. H. Metz, D. R. Tovell, I. M. Kerr and R. Williamson. 1972. Translation of RNA by L cell extracts: Effect of interferon. FEBS Lett 24, 273-277

Copyright © 2010 Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas